This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Regulus Appoints Paul C. Grint, M.D. As Chief Medical Officer

LA JOLLA, Calif., June 16, 2014 /PRNewswire/ -- Regulus Therapeutics Inc. (NASDAQ:RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, announced today the appointment of Paul C. Grint, M.D. to its executive management team as Chief Medical Officer. In his new role, Dr. Grint will be responsible for leading and expanding Regulus' microRNA clinical portfolio and will serve as a key member of its executive leadership team.  

Regulus Therapeutics Inc. Appoints Paul C. Grint, M.D. as Chief Medical Officer

"We are extremely pleased that Paul is joining Regulus at such an important time in the growth of our company.  Paul brings to Regulus over two decades of experience in biologics and small molecule drug development, including the successful development of numerous commercial products in oncology, anti-infectives and immunology in both domestic and international markets," said Kleanthis G. Xanthopoulos, Ph.D., President and CEO of Regulus. "Paul is a recognized expert in product development and his addition to our accomplished team will strengthen our capabilities to bring this next innovative wave of RNA therapies targeting microRNAs to patients in need."

Dr. Grint joined Regulus from Cerexa, Inc., a wholly-owned subsidiary of Forest Laboratories, Inc., where he served as President and was responsible for the oversight of anti-infective product development.  Prior to joining Cerexa, Inc., Dr. Grint served as Senior Vice President of Research at Forest Research Institute, Inc., Chief Medical Officer at Kalypsys, Inc., and Senior Vice President and Chief Medical Officer at Zephyr Sciences, Inc., and he also served in similar executive level positions at Pfizer Inc., IDEC Pharmaceuticals Corporation, and Schering-Plough Corporation.  Dr. Grint received his bachelor's degree from St. Mary's Hospital in London and his medical degree from St. Bartholomew's Hospital Medical College at the University of London.  Dr. Grint is a Fellow of the Royal College of Pathologists, a member of numerous professional and medical societies, and the author or co-author of over fifty scientific publications.

"The discovery of microRNAs in humans is one of the most exciting scientific developments in recent history and I believe that microRNA therapeutics will be a major class of new medicines with broad therapeutic application in many important diseases," said Paul C. Grint, M.D., Chief Medical Officer of Regulus.  "I am extremely excited about the clinical potential of targeting microRNAs – the ability to regulate entire pathways by controlling the translation of clusters of genes in disease pathways may prove to be a very powerful way to treat many complex diseases.  To date, Regulus has made tremendous progress in advancing its technology platform and I look forward to working with the accomplished Regulus team to build a meaningful clinical portfolio based on microRNAs."    

About microRNAs

microRNAs are small RNA molecules, typically 20 to 25 nucleotides in length, that do not encode proteins but instead regulate gene expression. More than 800 microRNAs have been identified in the human genome, and over one-third of all human genes are believed to be regulated by microRNAs.  A single microRNA can regulate entire networks of genes. As such, these molecules are considered master regulators of the human genome.  microRNA expression, or function, has been shown to be significantly altered or dysregulated in many disease states, including oncology, fibrosis, metabolic diseases, immune-inflammatory diseases and HCV. Targeting microRNAs with anti-miRs, chemically modified, single-stranded oligonucleotides, offers a unique approach to treating disease by modulating entire biological pathways and may become a new and major class of drugs with broad therapeutic application.

1 of 3

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 17,120.62 +68.89 0.40%
S&P 500 1,984.42 +10.79 0.55%
NASDAQ 4,457.9580 +33.2540 0.75%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto
Advertising Partners

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs